mProX™ Human CLEC7A Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;DCs

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

Infectious Research

Related Diseases

Aspergillosis; Candidiasis, Familial, 4

Gene ID

Human:64581

UniProt ID

Human:Q9BXN2

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CLEC7A, also known as C-type lectin domain family 7 member A, has various applications in different fields. In the context of lung adenocarcinoma, CLEC7A is one of the key genes regulating tumor infiltrating plasma cells (PC) and can be used to predict prognosis and treatment efficacy. It is also associated with shorter overall survival and can be used as a predictive marker. In the field of neuropathic pain, CLEC7A is involved in the activation of the Clec7a-MAPK/NF-Œ∫B-NLRP3 inflammasome axis, and its inhibition can ameliorate pain symptoms. In Parkinson's disease, CLEC7A is a therapeutic target for alleviating neuroinflammation. Additionally, CLEC7A is associated with disrupted epithelial permeability and the induction of inflammatory genes in the context of small intestinal absorptive cells. In severe COVID-19 cases, CLEC7A is one of the proteins that can predict disease progression and mortality. Overall, CLEC7A has implications in cancer prognosis, pain management, neurodegenerative diseases, intestinal health, and COVID-19 severity.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CLEC7A Stable Cell Line (S01YF-1023-PY295). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Jones (Verified Customer)

How does CLEC7A influence neuroinflammatory injury? Aug 20 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

CLEC7A is involved in neuroinflammatory processes, as seen in neuropathic pain, where its axis may be targeted for relieving pain through alleviating neuroinflammation. Aug 20 2020

chat Taylor Smith (Verified Customer)

What role does CLEC7A play in immune responses? Jul 08 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

CLEC7A expression in macrophages orchestrates the progression of acute kidney injury, indicating its crucial role in regulating macrophage phenotype during inflammatory responses. Jul 08 2023

Published Data

Fig.1 Influence of CLEC7A knock down on KLF4.

To further assess the role of KLF4 regulation by PRRs, an experiment was conducted involving RNA interference with siRNA targeting CLEC7A (Dectin-1) mRNA. A reduction of over 90% in CLEC7A mRNA and over 80% at the protein level was achieved through siCLEC7A treatment (not shown). An induction of KLF4 was observed in DCs stimulated with fungi, whereas KLF4 was diminished in DCs transfected with siCLEC7A and stimulated with LPS. An induction of KLF4 on the protein level was determined in siCLEC7A-treated DCs stimulated with either A. fumigatus, C. albicans, or LPS.

Ref: Czakai, Kristin, et al. "Krüppel-like Factor 4 modulates interleukin-6 release in human dendritic cells after in vitro stimulation with Aspergillus fumigatus and Candida albicans." Scientific Reports 6.1 (2016): 27990.

Pubmed: 27346433

DOI: 10.1038/srep27990

Research Highlights

Shu, Long. et al. "Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma." Cellular oncology (Dordrecht), 2023.
The main objective of this study is to determine the essential genes responsible for regulating tumor infiltrating plasma cells and to offer novel perspectives for advanced immunotherapy techniques. By analyzing these key genes, this research aims to provide a better understanding of the mechanisms behind PC infiltration and to suggest potential targets for immunotherapy. A thorough investigation of these genes could potentially lead to the development of effective treatments for cancer.
Shu, Long. et al. "Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma." Cellular oncology (Dordrecht), 2023.
Pubmed: 37814076 DOI: 10.1007/s13402-023-00883-w

Wu, Dan. et al. "Levo-tetrahydropalmatine ameliorates neuropathic pain by inhibiting the activation of the Clec7a-MAPK/NF-κB-NLRP3 inflammasome axis." Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023.
The therapeutic efficacy of current drugs for neuropathic pain (NP) is not entirely satisfactory due to its complex pathogenesis. Recent studies have suggested that neuroinflammation may contribute significantly to the development and progression of NP. Levo-tetrahydropalmatine (l-THP) has been widely utilized for chronic pain relief for many years, but its mechanisms in treating NP remain unclear. Therefore, further investigation is necessary to fully elucidate its potential effects against NP.
Wu, Dan. et al. "Levo-tetrahydropalmatine ameliorates neuropathic pain by inhibiting the activation of the Clec7a-MAPK/NF-κB-NLRP3 inflammasome axis." Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023.
Pubmed: 37741158 DOI: 10.1016/j.phymed.2023.155075